title: [Aildenafil citrate: a new potent and highly selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of aildenafil citrate, an oral phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction.
  
  
  METHODS
  Integrated analyses were made of 8-week, randomized, double-blind, placebo-controlled phase 2 clinical trials involving 250 men with mild-to-severe erectile dysfunction of various etiologies who received aildenafil citrate 30 or 60 mg (n = 167) or placebo (n = 83).
  
  
  RESULTS
  The statistic results of International Index of Erectile Function, Patient Sexual Encounter Profile (SEP) diaries and Global Assessment Question (GAQ) were significantly higher in the aildenafil citrate patients than in the placebo controls. The main drug-related adverse events were flushing, headache, dizziness and naupathia, which were mild and could be self-relieved.
  
  
  CONCLUSIONS
  The aildenafil citrate therapy significantly ameliorated erectile function and was well tolerated by a wide range of patients with erectile dysfunction.
authors.affiliation: Department of Urology, First Hospital of Peking University, Institute of Urology, Peking University, Beijing 100034, China. hezhanju@263.net
authors.forename: Zhan-ju
authors.initials: ZJ
authors.lastname: He
authors.forename: Kai
authors.initials: K
authors.lastname: Zhang
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
authors.forename: Ning-chen
authors.initials: NC
authors.lastname: Li
authors.forename: Yan-qun
authors.initials: YQ
authors.lastname: Na
authors.forename: Wen-jun
authors.initials: WJ
authors.lastname: Bai
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Wang
authors.forename: Ji-chuan
authors.initials: JC
authors.lastname: Zhu
authors.forename: Hui
authors.initials: H
authors.lastname: Jiang
authors.forename: Ren-pei
authors.initials: RP
authors.lastname: Yuan
authors.forename: Bao-fa
authors.initials: BF
authors.lastname: Hong
authors.forename: Tao
authors.initials: T
authors.lastname: Song
authors.forename: Yong
authors.initials: Y
authors.lastname: Yang
authors.forename: Dong-xi
authors.initials: DX
authors.lastname: Dai
mesh_terms: D000284:Administration, Oral; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D013450:Sulfones; C520604:aildenafil